6 completed, 2 terminated, 1 unknown, 1 withdrawn. 5 Phase 2, 4 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Terminated 2 |
| Phase 3 | 4 | Completed 2, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Celtic Pharma Development Services: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multisite Controlled Trial of Cocaine Vaccine TA-CD Vaccination, Placebo Injection - Cocaine Dependence | Phase 2 | Completed | Baylor College of Medicine | 300 | 2010-08-01 | 2017-03-15 |
| Tolerability Study of Xerecept® in Pediatric Patients XERECEPT - Brain Edema, Brain Tumor | Phase 1 / Phase 2 | Terminated | Celtic Pharma Development Services | 15 | 2010-06-01 | 2013-07-30 |
| TDT 067 Onychomycosis Study TDT067, Placebo, Transfersome - Onychomycosis | Phase 3 | Unknown | Celtic Pharma Development Services | 738 | 2010-04-01 | 2012-08-01 |
| TDT 067 Open Label Multi-Dose Onychomycosis Study TDT067 and Lamisil - Onychomycosis | Phase 2 | Completed | Celtic Pharma Development Services | 27 | 2009-12-01 | 2013-02-13 |
| Xerecept Intravenous Dose Escalation in Japanese and Caucasian Volunteers Xerecept 1.0, Xerecept 2.0, Xerecept 3.0 - Edema | Phase 1 | Completed | Celtic Pharma Development Services | 38 | 2008-12-01 | 2013-07-30 |
| Imaging Study of XERECEPT® Treatment for Peritumoral Brain Edema (PBE) Xerecept - Peritumoral Brain Edema, PRIMARY MALIGNANT and METASTATIC BRAIN TUMORS | Phase 2 | Terminated | PharmaNet | 60 | 2008-11-01 | 2009-01-09 |
| Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation TA-NIC, Placebo - Smoking | Phase 2 | Completed | Celtic Pharma Development Services | 522 | 2007-05-01 | 2011-06-08 |
| XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema hCRF, placebo hCRF - Brain Edema, Brain Tumor | Phase 3 | Withdrawn | Celtic Pharma Development Services | 120 | 2006-01-01 | 2008-01-03 |
| An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies hCRF [XERECEPT (corticorelin acetate injection)] - Brain Edema, Brain Tumor | Phase 3 | Completed | Celtic Pharma Development Services | 112 | 2005-07-01 | 2012-08-31 |
| XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors hCRF, placebo hCRF - Brain Edema, Brain Tumor | Phase 3 | Completed | Celtic Pharma Development Services | 200 | 2004-05-01 | 2014-08-13 |
Brain Neoplasms (5) · Edema (5) · Brain Edema (4) · Astrocytoma (3) · Onychomycosis (2) · Cocaine-Related Disorders (1) · Smoking (1) · Smoking Cessation (1)
Corticotropin-Releasing Hormone (4) · Terbinafine (2) · TA-NIC (1)
United States (8) · Canada (3)
William Shapiro, MD (3) · Eduardo Tschen, MD (2) · Stewart Goldman, MD (1) · Thomas R Kosten, M.D. (1)
PMID 19805702, PMID 23382470, PMID 24793366
R01DA025223 (1)